S&D, I am more positive than I was initially after reading remarks by Ziggy, Bourbon and others that I need to evaluate not as a Phase 3 type trial.
It would be good to hear/read what the actual dosing is for the Group of 6. I think most, if not all, were DZP naive and that 2-73 alone is the key. If anyone makes it into one of the road show meetings, please ask.
While I do not have a medical/pharma background it seems intuitive that if favorable blood concentrations are not reached for some patients on an oral dose due to gut-biome those patients could be given injectable doses or possibly eventually transdermal patches or other drug delivery such as inhalation.
Clearly what Anavex is seeking is the quickest path to market by loading the trial with participants that will likely get favorable blood concentrations on the oral dose. Hence one of the reasons for the Ariana and Anonixis collaborations.
Later if A2-73 is approved (which is looking more and more likely) Anavex can collaborate with Speciality Pharma Cos. that specialize in alternative drug delivery technology to gain approval of alternative delivery formulations to help a larger population of ALZ sufferers by bypassing the gut absorption path of the oral dosing regimen.
News 
Market Data 
Discover 
AI
